






KidneyAssociation of Admission, Nadir,
and Terminal Donor Creatinine With Kidney
Transplantation OutcomesGeorgina L. Irish1,2,3, P. Toby Coates2,3 and Philip A. Clayton1,2,3
1Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry, South Australian Health and Medical Research
Institute (SAHMRI), Adelaide, Australia; 2Department of Medicine, University of Adelaide, Adelaide, Australia; and 3Central and
Northern Adelaide Renal and Transplantation Service, Royal Adelaide Hospital, Adelaide, AustraliaIntroduction: When assessing deceased kidney donors, a key factor in organ acceptance and allocation is
donor kidney function. It is unclear whether terminal, admission, or the highest of terminal and admission
donor estimated glomerular filtration rate (eGFR) most predicts recipient outcomes.
Methods: We examined which measurement best predicts outcomes. Using data from the Australia and
New Zealand Organ Donation and Dialysis and Transplant Registries, we included adult recipients of
deceased donor kidney-only transplants over 2003 to 2019. We compared the 3 different exposure vari-
ables of admission, terminal, or highest eGFR. We created logistic regression models for delayed graft
function (DGF), multilinear regression models for 6- and 12-month eGFR, and Cox proportional hazards
models for graft loss, death censored graft failure and patient death.
Results: A total of 8971 transplant recipients were included. There was strong evidence of an association
between terminal, admission, and highest donor eGFR and DGF and recipient eGFR at 6 and 12 months.
The eGFR was a strong predictor of graft and death censored graft failure, but not patient death. Terminal
was a better predictor than admission and highest eGFR particularly for more contemporaneous
outcomes.
Conclusion: In assessing kidney donors, terminal eGFR were marginally better than admission and highest
at predicting outcomes. Terminal eGFR should be used in risk equations to predict hard clinical endpoints.
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idney transplantation is the best treatment for
most patients with end-stage kidney disease,
providing improved quality of life and survival while
using fewer resources.14 Deceased donor kidneys are
a scarce resource, with an imbalance between the num-
ber of people who would benefit from a kidney trans-
plant and the number of available organs. This
necessitates attempts to increase the number of kidneys
for transplantation, while maximizing the use of
reasonable-quality organs. Several deceased donor fac-
tors affect recipient outcomes.59 These donor factors
are incorporated into risk scores to help clinicians
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International Reports (2021) 6, 2075–2083and patients make decisions about stratifying the risk
of using particular organs, accepting organ offers,
and counselling patients on these risks.1013 These
scores are also included in formal transplantation allo-
cation algorithms in some countries.11,14
A key factor when making decision about kidney
allocation is the donor’s kidney function.15 This is
estimated by the so-called “terminal” or last recorded
pre-donation serum creatinine (SCr) or estimated
glomerular filtration rate (eGFR). This value is incor-
porated into risk scores.10 Elevated SCr occurs
commonly in deceased kidney donors.16,17 In the gen-
eral population, acute kidney injury (AKI) is associated
with the development of chronic kidney disease.18 In
kidney transplantation, although acutely elevated
donor creatinine is associated with delayed graft
function (DGF), there are conflicting reports in the
literature about its impact on graft failure.16 It is hy-
pothesized that the AKI seen in the peri-transplantation






























Figure 1. Histograms for donor estimated glomerular filtration rate (eGFR). Indication of distributions of the different exposure variables.
CLINICAL RESEARCH GL Irish et al.: Predicting Transplantation Outcomeselevated donor creatinine may not predict medium- to
long-term graft function. Elevated terminal creatinine
does increase the rate of organ discard, and thus re-
duces the organ pool.15,17
Although terminal creatinine is the most commonly
used marker of kidney function in donors, given the
rate of AKI in the intensive care population,18 the
initial or admission creatinine may be a better predictor
of long-term graft function. Acknowledging the fluc-
tuations in serum creatinine, the “best” recorded kid-
ney function might better represent long-term
function. Conversely, pre-hospitalization events such
as out-of-hospital cardiac arrest might make the
admission creatinine higher than the true baseline, and
this may settle during hospital admission, with termi-
nal creatinine being a better marker of baseline func-
tion. In our study, we examined whether terminal,
initial, or highest eGFR best predicted a number of
kidney transplantationrelated outcomes including
DGF, 6- and 12-month eGFR, and graft loss, death
censored graft failure, and patient death, to determine
which measurement should be used for risk prediction
and organ allocation.MATERIALS AND METHODS
Study Population
We extracted data from the Australia and New Zealand
Organ Donation (ANZOD) and Dialysis and Transplant2076(ANZDATA) Registries. We included adult recipients of
deceased-donor kidney-only transplants in Australia
and New Zealand over 2003 to 2019. Recipients were
excluded if they were <18 years old at the time of
transplantation, if their donors were <18 years of age,
if they received multiple types of organs, or if their
donors were from outside of Australia and New Zealand
(Figure 1). Recipients were also excluded if inadequate
information was available to calculate any of the donor
eGFR timepoints. Implausible values were excluded, as
they appeared to be due to data entry errors (ischemic
time >40 hours, donor body mass index [BMI] <10 or
>80 kg/m2, donor height <100 cm, recipient BMI >50
kg/m2, terminal or admission creatinine <15 mmol/l,
terminal or admission eGFR >200 mmol/l; total n ¼ 157,
1.7%). Few data were missing (<5%), so listwise
deletion was used to handle this rather than other
statistical techniques.Definitions
The original Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) equation was used to calculate
eGFR.19 Admission eGFR was calculated using the first
creatinine recorded on admission to hospital. Terminal
eGFR was calculated using the last creatinine prior to
organ procurement. Best eGFR was the highest of these
2 values. No other creatinine measurements are
collected in the registry. Delayed graft function wasKidney International Reports (2021) 6, 2075–2083
GL Irish et al.: Predicting Transplantation Outcomes CLINICAL RESEARCHdefined as the need for dialysis within the first 7 days
of transplantation or prior to 2015 if there was no
spontaneous fall (>10%) in SCr and dialysis was
required within 72 hours. Historically, this had been
recorded differently in the registry prior to 2015. Oli-
guria was defined as a urine output <500 ml in the
preceding 24 hours.
Outcome Measures
Six different outcomes were analyzed based on the
exposure of donor eGFR: delayed graft function, recipient
eGFR (at 6 months and 12 months), and survival (graft
loss, death censored graft failure, and patient death).
Overall graft loss was defined as time from trans-
plantation to return to dialysis, death with a func-
tioning graft, or re-transplantation. Death censored
graft failure was the same apart from censoring those
who died with a functioning graft. Patient death was
defined as the time from date of transplantation to
patient death, not censored at graft failure. Follow-up
was until 31 December 2019, and all survival times
were censored at the end of follow-up or loss to follow-
up. Exposure eGFR results were presented as 10 ml/min
per 1.73 m2 for ease of interpretation.
Covariates
The donor variables age, sex, ethnicity, BMI, cause of
death, diabetes, hypertension, smoking status, donation
after circulatory death status, and oliguria were all
analyzed as potential covariates. The following recipient
variables were examined; age, sex, ethnicity, BMI, pri-
mary renal disease, number of previous trans-
plantations, diabetes, hypertension, chronic lung
disease, ischemic heart disease, peripheral vascular dis-
ease, cerebrovascular disease, and smoking. In addition,
the transplant factors total ischemia time, peak panel
reactive antibody, and human leukocyte antigen mis-
matches at A, B, DR were considered as potential cova-
riates. The registry does not collect procurement biopsy
results, and thus this could be not included in the
analysis. Australia andNew Zealand do not routinely use
machine perfusion and these data are not collected in the
registry, and thus this was not a part of the analysis.
Data Analysis
The baseline characteristics of the study cohort were
expressed either as mean (SD) or as median (inter-
quartile range [IQR]), depending on the variable dis-
tribution. We created logistic regression models for the
outcome of delayed graft function adjusting for cova-
riates. Collinearity was assessed using variance inflation
factor. The linearity assumption was assessed through
categorization of continuous variables. Age at trans-
plantation was found not to be linear and was dealtKidney International Reports (2021) 6, 2075–2083with by using a restricted cubic spline. We checked for
interaction terms using forward elimination. Nonsig-
nificant variables were removed from the model using
backward elimination with a cutoff of P < 0.05. Vari-
ables were also considered confounders if they changed
the coefficient of the explanatory variable by >10%.
The different exposure variables were inserted into the
model. We compared the models using F test, adjusted
R2, and the HosmerLemeshow goodness of fit and the
C statistic (Supplementary Table S22).
Two multilinear regression models for the outcomes
of recipient eGFR at 6 and 12 months were created,
adjusting for covariates. Collinearity of different vari-
ables was assessed using the variance inflation factor.
The linearity assumption was assessed using scatter
plots of residual values for each continuous variable.
Effect modification was assessed for using the forward
elimination method. Nonsignificant variables were
removed from the model using backward elimination.
The different exposure variables were then assessed in
the different models. The Wald test was used to assess
the significance of exposure variable plus any interac-
tion terms. We then compared the variables of interest
for the different models using the F test and adjusted R2.
Three separate multivariable Cox proportional haz-
ards models were created to assess the outcomes of graft
loss, death censored graft failure, and patient death.
Nonlinear continuous variables were made categorical.
Interaction terms were assessed. The nonsignificant
variables were removed from the model using back-
ward elimination. We used scaled Schoenfeld residuals
to assess the proportional hazards assumption. Wald
statistics were used to assess the significance of expo-
sure variables. The models were assessed using the
Harrell C statistic and Akaike Information Criterion
(AIC). The cumulative incidence curves were presented
with the eGFR variable stratified into equal quartiles to
visually represent the difference in outcomes for the
different levels of eGFR.
Sensitivity Analysis
We undertook sensitivity analyses using serum creat-
inine instead of eGFR. There is no record in the ANZOD
registry as to whether donors received dialysis prior to
donation, and in this situation their SCr may be falsely
low. To try to account for this, we undertook a sensi-
tivity analysis by restricting the cohort to individuals
without oliguria using oliguria as a surrogate marker of
those requiring dialysis.
Statistical Analysis
All analyses were conducted in Stata/IC 16.1 (StataCorp,
College Station TX). The somersd package (Statistical
Software Components, Boston College Department of2077
Table 1. Demonstrating baseline characteristics for transplant
donors and recipients (N ¼ 8971)
Characteristic Value
Donor factors
Donor age, yr, median (IQR) 50 (38, 60)
Donor sex, male 5020 (56.0%)
Donor ethnicity
Caucasian 8083 (90.2%)





Donor body mass index, kg/m2, mean (SD) 28 (6)
Donor hypertension 2334 (26.3%)
Donor diabetes mellitus 522 (5.9%)
Donor smoker 5816 (64.8%)
Donation after brain death 7063 (78.7%)
Donor cause of death
Stroke 4470 (49.8%)
Road trauma 877 (9.8%)
Other trauma 798 (8.9%)
Hypoxia/anoxia 1716 (19.1%)
Cerebral tumor 64 (0.7%)
Other 1046 (11.7%)
Donor oliguria 976 (10.9%)
Donor eGFR, admission, mean (SD) 84 (26)
Donor eGFR, terminal, mean (SD) 89 (31)
Donor eGFR, highest, mean (SD) 97 (26)
Donor creatinine, admission, mean (SD) 90 (44)
Donor creatinine, terminal, mean (SD) 93 (76)
Donor creatinine, lowest, mean (SD) 75 (34)
KDRI, raw score, median (IQR) 1 (1, 2)
Recipient factors
Recipient age at transplantation, yr, median (IQR) 54 (45, 61)
Recipient sex (male) 5722 (63.8%)
Recipient ethnicity
Caucasian 5970 (72.4%)







Polycystic disease 1249 (14.0%)
Reflux nephropathy 609 (6.8%)
Hypertensive nephropathy 633 (7.1%)
Diabetic nephropathy 1367 (15.3%)
Other 1320 (14.8%)
Recipient body mass index, kg/m2, mean (SD) 27 (5)
Recipient smoker 4161 (47.0%)
Recipient diabetes mellitus 2047 (22.9%)
Recipient ischemic heart disease 1967 (22.0%)
Recipient peripheral vascular disease 1034 (11.5%)
Recipient cerebrovascular disease 589 (6.6%)
Recipient chronic lung disease 843 (9.4%)

















Total ischemia to nearest hour, mean (SD) 12 (5)
Delayed graft function 2800 (31.8%)
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2078Economics, Newton, MA) was used to calculate C sta-
tistics and their 95% confidence intervals.20
Ethical Approval
This research was conducted with approval from the
Royal Adelaide Hospital Human Research Ethics Com-
mittee HREC Reference number, HREC/17/RAH/408




A total of 8971 transplant recipients were included in
the analysis. The demographic details of recipients and
donors are displayed in Table 1. In all, 1585 patients
died (17.7%), and 2307 (25.7%) had graft loss. A total
of 72 patients were lost to follow-up (0.8%). Of the
donors, 74 (0.82%) were excluded, as their eGFR could
not be calculated because of missing data.
Exposure Measurement
The mean terminal eGFR was 89 ml/min per 1.73 m2
(SD ¼ 31), the mean admission eGFR was 84 ml/min per
1.73m2 (SD¼ 26), and the mean highest eGFRwas 97ml/
min per 1.73 m2 (SD ¼ 26). Terminal eGFR was higher
than admission eGFR for 5222 values, equal to admission
eGFR for 375 values, and less than admission eGFR for
3374 values. The results comparing the prediction of the
different exposures are in the supplementary material
(Supplementary Table S1). The unadjusted models are
included in the supplementary material (Supplementary
Tables S2S4).The variables included in the multivari-
able model are detailed in the supplementary material
(Supplementary Tables S5S22).
Delayed Graft Function
There was strong evidence of an association between
DGF and terminal donor eGFR when adjusting for
covariates (Table 2). The terminal and highest eGFRKidney International Reports (2021) 6, 2075–2083
Table 2. Model test statistics, aORs, and values for different
adjusted eGFR models for DGF
Admission eGFR per 10
ml/min per 1.73 m2
Terminal eGFR per 10
ml/min pr 1.73 m2












(95% CI) (0.87–0.93) (0.82–0.87) (0.81–0.87)
c2 Test 49 198 129
P value <0.0001 <0.0001 <0.0001
C statistic 0.75 0.76 0.75
(95% CI) (0.74–0.76) (0.72–0.75) (0.73–0.76)
aOR, adjusted odds ratio; CI, confidence interval; DGF, delayed graft failure; eGFR,
estimated glomerular filtration rate.
Table 3. Model test statistics and values for adjusted eGFR models














Adjusted b coefficient 0.58 0.69 0.80
(95% CI) (0.39–0.77) (0.53–0.85) (0.61–0.99)
F test statistic 10.8 21.4 20.1
P value <0.0001 <0.0001 <0.0001
12-mo eGFR
Adjusted b coefficient 0.63 0.62 0.83
(95% CI) (0.43–0.83) (0.46–0.78) (0.63–1.03)
F test statistic 10.4 14.7 16.75
P value <0.0001 <0.0001 <0.0001
eGFR, estimated glomerular filtration rate.
GL Irish et al.: Predicting Transplantation Outcomes CLINICAL RESEARCHhad lower odds of having delayed graft function
compared to admission eGFR (Figure 2). An interaction
term between donor sex and donor eGFR was included.
Because of the interaction term between donor sex and
donor eGFR, we presented the odds ratios (OR) for the
different models stratified by donor sex. Interestingly,
women had a lower risk of delayed graft function
compared to men. The models had moderate discrimi-
nation and were similar across all models (C statistics:
terminal C ¼ 0.76 [95% confidence interval {CI} ¼
0.720.75), admission C ¼ 0.75 [95% CI ¼ 0.74–0.76],
highest C ¼ 0.75 [95% CI ¼ 0.730.76]). The models
were well calibrated (Supplementary Table S23).
Recipient Kidney Function at 6 and 12 Months
There was strong evidence of an association between 6-
and 12-month recipient eGFR and donor eGFR at
different time points (Table 3). Terminal and highest
eGFR were better predictors of 6- and 12-month eGFR
compared to admission eGFR based on the test statis-
tics, although the degree of difference was not marked.Figure 2. Scatter plot for donor terminal compared to admission
estimated glomerular filtration rate (eGFR).
Kidney International Reports (2021) 6, 2075–2083Interaction terms were created between donor eGFR
and donor age, donor diabetic status, and donor
smoking status. The models performed similarly,
although adjusted R2 values were worse for donor
admission eGFR compared to terminal or highest GFR.
Graft Loss and Patient Death
Cox proportional hazard models showed that eGFR was
a predictor of graft survival across all models, although
the evidence was strongest for terminal donor eGFR
compared to both admission or highest eGFR (Table 4).
For death censored graft failure, Cox proportional
hazard models showed that eGFR had strong evidence of
an association across all models. Figure 3 shows the
different cumulative incidence curves for the different
donor eGFR variables. For terminal donor eGFR, there is
clear delineation between the cumulative incidence
curves for the different levels of eGFR. For the admission
donor eGFR, the lower 2 groups’ cumulative incidence
curves converge. For the highest donor eGFR, the lower
2 categories of eGFR groups cross. For patient survival,
there was no evidence of an association between donor
eGFR and survival, with no statistically significant P
values and confidence intervals that crossed 1.
For graft loss and patient death, there was an
interaction between donor eGFR and donor age. For
death censored graft failure, there was an interaction
between donor eGFR and age and between donor eGFR
and donor BMI. For all the Cox models, the C statistics
showed moderate discrimination, and the AIC demon-
strated similar model performance.
Sensitivity Analyses
Sensitivity analyses were undertaken for all outcomes
using SCr instead of eGFR. These did not change any of
the conclusions (Supplementary Table S24). In a
restricted cohort that excluded individuals with oli-
guria, there was little change in the model’s perfor-
mance (Supplementary Table S25).2079














Adjusted HR 0.98 0.97 0.96
(95% CI) (0.96–0.99) (0.95–0.98) (0.94–0.98)
Wald statistic 6.37 19.7 15.22
P value 0.04 <0.0001 0.0005
Death censored graft failure
Adjusted HR 0.95 0.94 0.94
(95% CI) (0.93–0.98) (0.92–0.96) (0.92–0.97)
Wald statistic 13.1 33.5 21.6
P value 0.01 <0.0001 0.0002
Patient death
Adjusted HR 0.99 0.98 0.98
(95% CI) (0.97–1.01) (0.96–1.00) (0.96–1.00)
Wald statistic 0.85 4.61 3.12
P value 0.6 0.09 0.2
CI, confidence interval; eGFR, estimated glomerular filtration rate; HR, hazard ratio.
CLINICAL RESEARCH GL Irish et al.: Predicting Transplantation OutcomesDISCUSSION
We present a detailed prediction study assessing donor
kidney function at different time points prior to organ
procurement to predict clinically relevant outcomes.
This study confirms a number of expected findings,
particularly that donor kidney function was strong
evidence of an association with recipient outcomes. The
evidence of this association was stronger for outcomes
that occurred earlier posttransplantation. For the short-
term outcome of DGF, there was strong evidence of
associations between terminal, admission, and highestFigure 3. Cumulative hazard function for death censored graft failure.
2080donor eGFR. Terminal donor eGFR, however, best
predicted DGF followed by highest and then the
admission donor eGFR. For the outcome of recipient 6-
and 12-month eGFR, all donor eGFR time points had
strong evidence of an association. Both terminal and
highest donor eGFR had stronger evidence of an asso-
ciation than admission eGFR for 6 and 12-month
recipient eGFR. For longer terminal outcomes, donor
eGFR had stronger evidence of an association with
death censored graft failure. This too, had the greatest
evidence of an association with terminal followed by
highest donor eGFR. This was also seen for the outcome
of graft loss; however, evidence of an association was
not as strong. There was no evidence of an association
between donor eGFR and patient death. The strength of
the associated effect was more pronounced for events
than for earlier posttransplantation. This is an antici-
pated finding, because for long-term outcomes such as
graft loss and patient death, they are more likely to be
affected by recipient factors.
The absolute difference in mean eGFR between ter-
minal and highest was 12.2 ml/min per 1.73 m2 (mean
eGFR: terminal 89 [SD ¼ 31], admission 84 [SD ¼ 26],
highest 97 [SD ¼ 26] ml/min per 1.73 m2). There was
strong evidence for a difference in prediction when
using terminal compared to admission eGFR to predict
DGF. For longer-term outcomes, there was no differ-
ence in predicting outcomes when using the different
donor eGFR measurements. For terminal donor eGFR,
there was clear delineation between the cumulative
incidence curves for the different levels of eGFR, sug-
gesting that this exposure variable may be helpful forKidney International Reports (2021) 6, 2075–2083
GL Irish et al.: Predicting Transplantation Outcomes CLINICAL RESEARCHpredicting outcome from all levels of eGFR. For highest
and admission eGFR, for the lower categories of eGFR,
the cumulative incidence curves crossed or joined. It
could be argued that for the lower categories of eGFR,
it is more important to be able to predict the outcomes
than for higher levels of eGFR when there will more
clearly be a survival advantage. There is a greater as-
sociation between donor eGFR and early post-
transplantation outcomes. For example, terminal eGFR
compared to admission eGFR is better at predicting
DGF that is the earlier posttransplantation outcome.
In certain instances with high-risk recipients, it may
be particularly important to avoid DGF. For these cir-
cumstances, the use of terminal (rather than admission
or highest) donor eGFR in conjunction with the other
donor, recipient, and transplantation risk factors may
aid in clinical decision making
The main study that has previously examined the
timing of kidney function in donors to predict re-
cipients outcomes was a study by Chiles et al.21 They
used the Organ Procurement and Transplantation
Network /United Network for Organ Sharing data to
assess whether admission or terminal creatinine was
better able for discriminating the outcomes of graft or
death censored failure at 1 and 3 years, using receiver
operator characteristic curves.21 They were unable to
find a clinically meaningful difference in C statistics at
either the 1- or 3-year time point (1 year: C ¼ 0.6090 vs.
0.6058, P ¼ 0.001; 3 years: C ¼ 0.5985 vs. 0.5957, P ¼
0.001). This study suggested that either admission or
terminal creatinine could be used to assess donor kid-
ney function.
Overall, in our study, when assessing the different
exposure variables for the different outcomes, terminal
eGFR and highest eGFR performed slightly better than
admission eGFR, although the difference between these
outcomes were minimal. We assessed a number of
different outcome measurements and found that the
exposure variables performed similarly in the models
for the different outcomes. This reinforces that current
transplantation practice, in which terminal eGFR is
most commonly used for risk assessment, is sound.
There are a number of strengths to our study. It is a
comprehensive assessment of a number of different
outcome variables that have not been previously
examined. The study also included a large number of
patients. There were few missing data, and the study
captured most kidney transplantations performed in
Australia and New Zealand over this time period. In
addition, we undertook sensitivity analyses to assess
whether eGFR or SCr was a better explanatory variable.
Our study had the limitations associated with using
registry data. Also, analysing only those individuals
who have already undergone transplantation meansKidney International Reports (2021) 6, 2075–2083that patients who had a lower terminal eGFR may have
been excluded from the study, which may have
contributed to selection bias. We used eGFR rather
than SCr, as eGFR accounts for demographic and clin-
ical variables in providing an estimate of filtration rate.
GFR is ideally measured, however, during a steady
state of creatinine,22and during intensive care admis-
sion and intercurrent illness this may not be the case.23
Because of a lag in creatinine accumulation when the
glomerular filtration rate changes, this will also be an
issue when using creatinine as a marker of kidney
function. This was demonstrated when there was no
difference in outcome when SCr was used for the
sensitivity analyses. In addition, using creatinine as a
marker of kidney function does not account for the
impact on creatinine production from muscle wasting
states, diet, or medications.22 Perhaps further research
could be considered regarding whether measuring
donor glomerular filtration rate by either traditional or
novel methods would provide better predictive ability
than SCr or eGFR.
In conclusion, this analysis suggests that terminal
eGFR is a better predictor of a number of clinically
important transplantation outcomes, although the dif-
ferences were not large. Given this, as a component of
prediction of graft outcomes, we support the use of
terminal eGFR to assess donor kidney function.DISCLOSURE
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Table S1. Table comparing prediction for different donor
eGFR2081
CLINICAL RESEARCH GL Irish et al.: Predicting Transplantation OutcomesTable S2. Test statistics and model values for 3 exposure
variables of terminal, admission and highest eGFR
different unadjusted models, for outcome of DGF
Table S3. Test statistics and model values for 3
exposure variables of terminal, admission and highest
eGFR different unadjusted models, for outcome of 6
and 12 month eGFR. Assessment of model fit included
in table
Table S4. Test statistics and model values for 3 exposure
variables of terminal, admission and highest eGFR
different unadjusted models, for survival outcomes
Table S5. Coefficients, 95% confidence intervals, and P
values for exposure of admission eGFR per 10 ml/min
per 1.73 m2 outcome of delayed graft function
Table S6. Coefficients, 95% confidence intervals, and P
values for exposure of terminal eGFR per 10 ml/min per
1.73 m2 outcome of delayed graft function
Table S7. Coefficients, 95% confidence intervals and P
values for exposure of highest eGFR per 10 ml/min per
1.73 m2 outcome of delayed graft function
Table S8. Coefficients, 95% confidence intervals, and P
values for exposure of admission eGFR per 10 ml/min
per 1.73 m2 outcome of recipient 6-month eGFR
Table S9. Coefficients, 95% confidence intervals, and P
values for exposure of terminal eGFR per 10 ml/min per
1.73 m2 outcome of recipient 6-month eGFR
Table S10. Coefficients, 95% confidence intervals and P
values for exposure of highest eGFR per 10 ml/min per
1.73 m2 outcome of recipient 6-month eGFR
Table S11. Coefficients, 95% confidence intervals, and P
values for exposure of admission eGFR per 10 ml/min
per 1.73 m2 outcome of recipient 12-month eGFR
Table S12. Coefficients, 95% confidence intervals, and P
values for exposure of terminal eGFR per 10 ml/min per
1.73 m2 outcome of recipient 12-month eGFR
Table S13. Coefficients, 95% confidence intervals, and P
values for exposure of highest eGFR per 10 ml/min per
1.73 m2 outcome of recipient 12-month eGFR
Table S14. Coefficient, 95% confidence intervals, and P
values for exposure of admission eGFR per 10 ml/min
per 1.73m2 outcome graft loss
Table S15. Coefficient, 95% confidence intervals, and P
values for exposure of terminal eGFR per 10 ml/min per
1.73 m2 outcome graft loss
Table S16. Coefficient, 95% confidence intervals, and P
values for exposure of highest eGFR per 10 ml/min per
1.73 m2 outcome graft loss
Table S17. Coefficient, 95% confidence intervals, and P
values for exposure of admission eGFR per 10 ml/min
per 1.73 m2 outcome death censored graft failure
Table S18. Coefficient, 95% confidence intervals,
and P values for exposure of terminal eGFR per 10
ml/min per 1.73 m2 outcome death censored graft
failure2082Table S19. Coefficient, 95% confidence intervals, and P
values for exposure of highest eGFR per 10 ml/min per
1.73 m2 outcome death censored graft failure
Table S20. Coefficient, 95% confidence intervals, and P
values for exposure of admission eGFR per 10 ml/min
per 1.73 m2 outcome patient death
Table S21. Coefficient, 95% confidence intervals, and P
values for exposure of terminal eGFR per 10 ml/min per
1.73m2 outcome patient death
Table S22. Coefficient, 95% confidence intervals, and P
values for exposure of highest eGFR per 10 ml/min per
1.73 m2 outcome patient death
Table S23. Test statistics and model values for 3 exposure
variables of terminal, admission, and highest eGFR
different adjusted models, for 3 different outcomes DGF,
6- and 12-month eGFR, and graft loss, death censored
graft failure, and patient death (complete table for all out-
comes and exposure variables including test statistics and
assessment of model performance)
Table S24. Sensitivity analysis: terminal, admission, and
lowest serum creatinine used instead of eGFR to predict
outcomes. Test statistics and models values for 3
exposure variables of terminal, admission, and highest
eGFR different models, for 3 different outcomes DGF, 6-
and 12-month eGFR, and graft loss, death censored graft
failure, and patient death
Table S25. Sensitivity analysis: restricted to those without
oliguria. Test statistics and model values for 3 exposure
variables of terminal, admission, and highest eGFR
different models, for 3 different outcomes DGF, 6- and
12-month eGFR, and graft loss, death censored graft
failure, and patient death
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